By Joseph Burns, from the Volume XXV No. 18 – December 24, 2018 issue
CEO SUMMARY: With the year end approaching, lab buyers and sellers are working to finalize deals that may have been in discussion for months. The first big lab acquisition for this season came on Nov. 27, when Quest Diagnostics announced it was acquiring Boyce and Bynum Pathology Laboratories of Columbia, Mo. The pathologists will keep
By Robert Michel, from the Volume XXV No. 17 – December 3, 2018 issue
Another long-established regional laboratory company is about to be acquired. On November 27, Boyce and Bynum Pathology Laboratories of Columbia, Mo., disclosed that it had entered an agreement to be acquired by Quest Diagnostics Inc. Notably, the press release about the agreement states that the anatomic pathology division, Boyce and Bynum Professional Services, Inc., and the
By Joseph Burns, from the Volume XXV No. 4 – March 5, 2018 issue
CEO SUMMARY: In the midst of expanding their toxicology testing services nationally, DrugScan and DSI Medical Services (collectively Toxicology Holdings Inc.) hired a brokerage firm last year to pursue a sale of the two toxicology companies. Multiple potential buyers responded with interest. The buyer, ACM Global Laboratories—owned by a health system in Rochester, N.Y.—saw the
By Bill Dugan, from the Volume XXIV, No. 4 – March 13, 2017 issue
This is an excerpt from a 1,021-word article in the March 13, 2017, issue of THE DARK REPORT. The complete article is available for a limited time to all readers, and available at all times to paid members of the Dark Intelligence Group.
CEO SUMMARY: Is this year’s early spate of deals involving the sales of hospital lab outreach
By Joseph Burns, from the Volume XXIII No. 5 - April 11, 2016 issue
CEO SUMMARY: Two different business models of clinical laboratory consulting have now been brought together. Chi consultants have long focused on analytics and improving outreach performance, among other areas of lab performance. By contrast, Accumen’s business model is nontraditional and centers upon a shared-savings partnership with a hospital or health system. Executives at Accumen are betting that a combination of both types
By R. Lewis Dark, from the Volume XXIII No. 4 – March 21, 2016 issue
WHEN IT COMES TO THE CLINICAL LABORATORY BUSINESS, generally included in the lab industry’s Pantheon of Greatest Physician (Pathologist) Businessmen are Paul A. Brown, MD, and James B. Powell, MD. I’d like to nominate another physician to this list: Marc D. Grodman, MD.
During the 1970s and 1980s, Brown and Powell—both pathologists— founded and led two
By Robert Michel, from the Volume XXIII No. 3 – February 29, 2016 issue
IN RECENT WEEKS, the nation’s two largest lab companies reported fourth quarter and full-year earnings for 2015. The earnings reports reveal how the paths of the two companies are diverging.
The companies are diverging because of a major acquisition made in February 2015, by Laboratory Corporation of America. LabCorp bought Covance Inc. in a deal valued at
By Robert Michel, from the Volume XXII NO. 5 - March 30, 2015 issue
BOTH OF THE NATION’S LARGEST clinical laboratory companies reported increased specimen volume as a result of the Accountable Care Act (ACA), as noted in their respective fourth quarter and full-year earnings reports.
CEO SUMMARY: It is one of the 10 largest lab companies in the United States. Thus, if Pathology Associates Medical Laboratories in Spokane, Washington, were to be sold, it would trigger a major shift in the competitive market for lab testing services-both in the Pacific Northwest and nationally. Owners and executives at PAML have neither confirmed nor denied the ongoing rumors
By Robert Michel, from the Volume XXI NO. 2 – February 3, 2014 issue
Last month, it was announced that Solstas Lab Partners of Greensboro, North Carolina, had agreed to be sold to Quest Diagnostics Incorporated. The sales price is $570 million and financial analysts on Wall Street estimate that the annual revenue at Solstas Lab Partners is about $350 million. This would indicate that Quest Diagnostics paid a
